Scotland-based Hilltop Leaf has confirmed it has completed a successful Medicines and Healthcare products Regulatory Agency (MHRA) inspection.
The inspection was carried out following an application for a Manufacturer’s Specials licence in line with The Human Medicines Regulations 2012.
The resulting licence will confirm Hilltop Leaf – a medicinal cannabis cultivation and extraction business – is a functioning GMP facility.
Read more: Hilltop Leaf’s giant cannabis farm in Scotland boosted by £2m investment round
In a statement, the Hilltop Leaf board of directors commented: “We are delighted to have reached this critical milestone. Once again our teams have worked in cross divisional harmony to ensure our facility, systems and procedures meet the incredibly high quality standards required by the MHRA.
“Our new licence will enable us to operate commercially to meet clinical patients’ needs.
“This news goes some way to lending further credibility to our ambitious plans. We greatly appreciate all the support from our shareholders, staff and other stakeholders.”
In October 2021, the company was issued a high THC cannabis cultivation licence by Home Office Controlled Drug licensing, which enables the company to undertake cultivation activities with certain schedules of Controlled Drugs: Schedule 1 Cultivation High THC Cannabis.
Earlier in 2021, Hilltop Leaf raised £2m to fund its cultivation and extraction facilities.
Hilltop Leaf is in the process of developing a growing operation near Dumfries in south Scotland that has the potential to be one of the largest in the UK and the first in Scotland.
The seed funding round was carried out to support the development of the operation and go towards ‘creating a science-led Scottish pharmaceutical product while bringing jobs and innovation’ to the region.
[activecampaign form=31]
